Amplify Bio's two-year AI×Bio bet pays off with 20+ portfolio companies
GabriCorso · x · 2026-10-21
Amplify Bio marks two years with four dedicated investors, an industry-leading advisor roster, and 20+ portfolio companies including Tahoe (virtual cell models from hyperscale single-cell data), Axiom (world's largest toxicology dataset), and Bexorg (whole-brain perfusion for real-world brain/drug interactions). The fund says it may have underestimated the AI×Bio wave, and announced Madelyn Heart joining as Head of Bio Platform to provide community, ops, and connections beyond capital.
More from Venture
- FirstMark portfolio in one day: Daytona Series B, Baba Series A, Gradium's on-device voice model — mattturck · 2026-10-21
- Developer claims $7M in sales by wiring X's API to Claude — EXM7777 · 2026-10-21
- Data center debt being repackaged to pension funds, likened to subprime bubble — SumitGup · 2026-10-21
- SEO veteran maps a 3-step path from practice sites to high-competition keywords — gefei55 · 2026-10-21
- Blogger proposes seeding universal high income with an annual AI-stock levy for every US citizen — signulll · 2026-10-21
- Fireworks AI Seeks New Round at $30-40B Valuation Months After $17.5B Raise — mjdramstead · 2026-10-21